- Title: Subtitle
- Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL
- Creators
- Krish Patel - 1Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WAYoungil Koh - Seoul National University HospitalSabarish Ayyappan - University of IowaYasmin Karimi - University of Michigan–Ann ArborIzidore S. Lossos - Sylvester Comprehensive Cancer CenterAkil Merchant - Cedars-Sinai Medical CenterPhuong Lee - 7Xencor, Inc., Monrovia, CAJianhua Jin - 7Xencor, Inc., Monrovia, CARaphael Clynes - 7Xencor, Inc., Monrovia, CAJitendra Kanodia - 7Xencor, Inc., Monrovia, CAMichael T. Chiarella - 7Xencor, Inc., Monrovia, CASteve Kye - 7Xencor, Inc., Monrovia, CAJean-Marie Michot - Institut Gustave Roussy
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.140(Supplement 1), pp.12066-12067
- DOI
- 10.1182/blood-2022-158042
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984361733702771
Abstract
Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL
Blood, Vol.140(Supplement 1), pp.12066-12067
11/15/2022
DOI: 10.1182/blood-2022-158042
Details
Metrics
17 Record Views